Revenue Growth
Q1 revenues were $737 million, up 6% from Q1 last year, with contributions from recent acquisitions and a strong order backlog of approximately $2.1 billion.
Strong Order Backlog
Order backlog ended the quarter at approximately $2.1 billion, providing solid revenue visibility and a strong foundation for profitable growth. The Life Sciences order backlog alone was $1.2 billion.
Positive Developments in Energy Sector
The energy sector, particularly nuclear, is benefiting from renewed investment and favorable government policy, with ongoing CANDU refurbishment and potential growth in small module reactor programs.
Recognition and Awards
ATS was included in Time Magazine's inaugural list of Canada's best companies 2025, ranking #1 in the engineering, manufacturing, and medical technology category.
Healthy Life Sciences Funnel
The diversified Life Sciences opportunity funnel remains strong, with wins across submarkets, and Comecer being a partner of choice for radio pharma customers.